Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin

Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has had its share of bad press. However, the company is positioned as perceptions of this substance are beginning to change. A recent article discussing this reads, “Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States. This view has come under criticism as recent studies surrounding the substance show otherwise. The public’s opinion, state guidelines and pharmaceutical development of psychedelic products are moving towards growing acceptance and legalization.”

To view the full article, visit

About Cybin Inc.

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at        

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Cybin Inc. CYBN. Bookmark the permalink.

Comments are closed.